Reply to Hopper, Nguyen, and Li

Affiliations

Comment

Ana S Salazar et al. JNCI Cancer Spectr. 2021.

. 2021 Jun 14;5(4):pkab052.

doi: 10.1093/jncics/pkab052. eCollection 2021 Aug.

¹ Department of Surgery, Division of Public Health Sciences, Washington University School of Medicine, St Louis, MO, USA.

No abstract available

Comment on

Chemoprevention Agents to Reduce Mammographic Breast Density in Premenopausal Women: A Systematic Review of Clinical Trials.
Salazar AS, Rakhmankulova M, Simon LE, Toriola AT. Salazar AS, et al. JNCI Cancer Spectr. 2021 Jan 22;5(1):pkaa125. doi: 10.1093/jncics/pkaa125. eCollection 2021 Feb. JNCI Cancer Spectr. 2021. PMID: 33554041 Free PMC article.
RE: Chemopreventive Agents to Reduce Mammographic Breast Density in Premenopausal Women: A Systematic Review of Clinical Trials.
Hopper JL, Nguyen TL, Li S. Hopper JL, et al. JNCI Cancer Spectr. 2021 Jun 14;5(4):pkab051. doi: 10.1093/jncics/pkab051. eCollection 2021 Aug. JNCI Cancer Spectr. 2021. PMID: 34377932 Free PMC article. No abstract available.

1. Hopper JL, Nguyen TL, Li S.. Chemoprevention, mammographic breast density and breast cancer. JNCI Cancer Spectr. 2021;1–5. - PMC - PubMed
1. Pettersson A, Graff RE, Ursin G, et al. Mammographic density phenotypes and risk of breast cancer: a meta-analysis. J Natl Cancer Inst. 2014;106(5):dju078. - PMC - PubMed
1. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007;356(3):227–236. - PubMed
1. Engmann NJ, Golmakani MK, Miglioretti DL, et al. Population-attributable risk proportion of clinical risk factors for breast cancer. JAMA Oncol. 2017;3(9):1228-1236. doi:10.1001/jamaoncol.2016.6326. - PMC - PubMed
1. Kontos D, Winham SJ, Oustimov A, et al. Radiomic phenotypes of mammographic parenchymal complexity: toward augmenting breast density in breast cancer risk assessment. Radiology. 2019;290(1):41–49. - PMC - PubMed